The efficacy of vigliptin tablets is hypoglycemia, and the side effects include neurological lesions, digestive system lesions, muscle connective tissue lesions, infections, vascular lesions, metabolic and nutritional lesions, and so on. Viglitin tablets belong to the dipeptidyl peptidase 4 inhibitors, which can inhibit the activity of dipeptidyl peptidase 4 (DPP-4) and promote glucose-dependent insulin secretion, thus lowering blood glucose, and are mostly used for the treatment of type 2 diabetes mellitus in clinical practice. Adverse effects such as neurological lesions (e.g. headache, dizziness, etc.), digestive system lesions (e.g. constipation, etc.), muscle connective tissue lesions (e.g. arthralgia, etc.), infections (e.g. upper respiratory tract infections, nasopharyngitis, etc.), vascular lesions (e.g. peripheral edema, etc.), and metabolic and nutritional pathologies (e.g. hypoglycemia) may occur with the use of the drug as monotherapy. It should be noted that the use of this drug is prohibited for those who are allergic to any component of the drug, pregnant women, nursing mothers, the drug is not suitable for patients with type 1 diabetes, and can not be used to treat diabetic ketoacidosis, and the drug is not recommended for use in children and adolescent patients. Patients should follow the doctor’s instructions to use Vildagliptin tablets, if any discomfort occurs during the use of the drug, persistent unrelieved or more serious symptoms, you should consult a doctor in a timely manner.